Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies
Over the past two decades, the field of multiple sclerosis (MS) has been transformed by the rapidly expanding arsenal of new disease modifying therapies (DMTs). Current DMTs for MS aim to modulate innate and adaptive immune responses toward a less inflammatory phenotype. Since the immune system is a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.02954/full |
| _version_ | 1818837292627787776 |
|---|---|
| author | Esther Melamed Michael William Lee |
| author_facet | Esther Melamed Michael William Lee |
| author_sort | Esther Melamed |
| collection | DOAJ |
| description | Over the past two decades, the field of multiple sclerosis (MS) has been transformed by the rapidly expanding arsenal of new disease modifying therapies (DMTs). Current DMTs for MS aim to modulate innate and adaptive immune responses toward a less inflammatory phenotype. Since the immune system is also critical for identifying and eliminating malignant cells, immunosuppression from DMTs may predictably increase the risk of cancer development in MS patients. Compared with healthy controls, patients with autoimmune conditions, such as MS, may already have a higher risk of developing certain malignancies and this risk may further be magnified by DMT treatments. For those patients who develop both MS and cancer, these comorbid presentations create a challenge for clinicians on how to therapeutically address management of cancer in the context of MS autoimmunity. As there are currently no accepted guidelines for managing MS patients with prior history of or newly developed malignancy, we undertook this review to evaluate the molecular mechanisms of current DMTs and their potential for instigating and treating cancer in patients living with MS. |
| first_indexed | 2024-12-19T03:20:11Z |
| format | Article |
| id | doaj.art-05e0361bfeab46be99f23b01bc7ab619 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T03:20:11Z |
| publishDate | 2020-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-05e0361bfeab46be99f23b01bc7ab6192022-12-21T20:37:46ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-01-011010.3389/fimmu.2019.02954497041Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying TherapiesEsther Melamed0Michael William Lee1Department of Neurology, Dell Medical School, Austin, TX, United StatesDepartment of Oncology, Department of Medical Education, Dell Medical School, Austin, TX, United StatesOver the past two decades, the field of multiple sclerosis (MS) has been transformed by the rapidly expanding arsenal of new disease modifying therapies (DMTs). Current DMTs for MS aim to modulate innate and adaptive immune responses toward a less inflammatory phenotype. Since the immune system is also critical for identifying and eliminating malignant cells, immunosuppression from DMTs may predictably increase the risk of cancer development in MS patients. Compared with healthy controls, patients with autoimmune conditions, such as MS, may already have a higher risk of developing certain malignancies and this risk may further be magnified by DMT treatments. For those patients who develop both MS and cancer, these comorbid presentations create a challenge for clinicians on how to therapeutically address management of cancer in the context of MS autoimmunity. As there are currently no accepted guidelines for managing MS patients with prior history of or newly developed malignancy, we undertook this review to evaluate the molecular mechanisms of current DMTs and their potential for instigating and treating cancer in patients living with MS.https://www.frontiersin.org/article/10.3389/fimmu.2019.02954/fullmultiple sclerosisdisease modifying therapycancertreatment of autoimmune diseasemultiple sclerosis drug mechanismcancer treatment |
| spellingShingle | Esther Melamed Michael William Lee Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies Frontiers in Immunology multiple sclerosis disease modifying therapy cancer treatment of autoimmune disease multiple sclerosis drug mechanism cancer treatment |
| title | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies |
| title_full | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies |
| title_fullStr | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies |
| title_full_unstemmed | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies |
| title_short | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies |
| title_sort | multiple sclerosis and cancer the ying yang effect of disease modifying therapies |
| topic | multiple sclerosis disease modifying therapy cancer treatment of autoimmune disease multiple sclerosis drug mechanism cancer treatment |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2019.02954/full |
| work_keys_str_mv | AT esthermelamed multiplesclerosisandcancertheyingyangeffectofdiseasemodifyingtherapies AT michaelwilliamlee multiplesclerosisandcancertheyingyangeffectofdiseasemodifyingtherapies |